Search

Displaying results 2471 - 2480 of 10000 in total
  1. Drug

    Quavonlimab

    go.drugbank.com/drugs/DB16422
    Investigational

    Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).

  2. Drug

    MK-1064

    go.drugbank.com/drugs/DB15028
    Investigational

    MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).

  3. Drug

    MK-6325

    go.drugbank.com/drugs/DB15249
    Investigational

    MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)).

  4. Drug

    MK-8666

    go.drugbank.com/drugs/DB14937
    Investigational

    MK-8666 is under investigation in clinical trial NCT01971554 (Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)).

  5. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  6. Drug

    LI-301

    go.drugbank.com/drugs/DB05509
    Experimental

    It has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism at mu-opioid receptors. … LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water.

  7. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting … [L51998,A264878] This novel mechanism of action is effective even in the presence of inhibitors towards factors VIII or IX, as it essentially skips the intrinsic pathway in which factors VIII and IX participate

  8. Drug

    ABT-510

    go.drugbank.com/drugs/DB05434
    Investigational

    ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth. … It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.

  9. Drug

    Crovalimab

    go.drugbank.com/drugs/DB16128
    ApprovedInvestigational

    Crovalimab is a humanized monoclonal antibody and complement C5 inhibitor.[L50908] It consists of two heavy chains (451 amino acid residues each) and two light chains (217 amino acid residues each). … [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

    Synonyms: IGHJ4*01 (100%)) (9.8.15) (1-123)-HOMO SAPIENS IGHG1*, Complement c5 inhibitory humanized recycling monoclonal antibody (rg-6107 )
  10. Drug

    Pancrelipase protease

    go.drugbank.com/drugs/DB11066
    ApprovedInvestigational

    [L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion. … Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.

    Mixtures: KREON MIKRO 5000 IU MINIMIKROSFER,, Pancrease Mt 20